查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701263

結核病診斷市場規模、佔有率、趨勢分析報告（按類型、最終用途、地區、細分市場預測），2025-2030 年

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Type (Detection Of Latent Infection, Phage Assay, Nucleic Acid Testing), By End-use (Diagnostic Laboratories, Hospitals & Clinic), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

結核病診斷市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球結核病診斷市場規模預計到2030年將達到31.8億美元，2025年至2030年期間的複合年成長率為5.8%。

干擾素-γ釋放試驗（IGRA）、血清學技術和核酸檢測等先進診斷方法的出現，使得診斷劑的利用率提高了。此外，抗原檢測等即時診斷（POC）技術也提高了結核病的診斷率。

這些先進的方法，包括 POC 診斷，價格實惠、準確、方便且能快速提供結果。此外，結核病負擔的增加是市場成長的主要動力。根據世界衛生組織（WHO）的估計，2014年全球結核病病例數約為960萬人。如此高的發病率促使政府、醫療保健組織、研究機構和市場相關人員紛紛採取行動遏制感染疾病。

提高高負擔地區的篩檢率、負擔得起的診斷方法、先進的調查方法、快速的臨床決策和降低死亡率是發展的重點。這些努力的最終結果是預防和治療診斷率的提高。這導致診斷測試的需求激增，擴大了結核病診斷市場。

結核病診斷市場報告重點

  • 受結核病患者病率上升的推動，潛在感染檢測領域（皮膚測試和 IGRA）將在 2024 年佔據 40.59% 的市場佔有率，佔據市場主導地位。
  • 預計藥物抗藥性（DST）將在預測期內實現最快的複合年成長率。藥敏試驗評估結核菌對各種抗生素的敏感性，並確定哪些藥物對治療疾病有效。
  • 2024 年，診斷實驗室部門佔據了最大的收入佔有率，並成為結核病診斷市場的驅動力。
  • 受醫療機構結核病檢測率上升的推動，醫院和診所部門預計將經歷強勁成長。
  • 預計亞太地區結核病診斷市場將在 2024 年佔據市場主導地位，收益佔有率為 37.18%，預計在預測期內將以最快的速度成長。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 結核病診斷市場變數、趨勢和範圍

  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
  • 結核病診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19影響分析
    • 案例研究

第4章結核病診斷市場：按類型估計和趨勢分析

  • 2024 年及 2030 年各類型市場佔有率
  • 細分儀表板
  • 全球結核病診斷市場：按類型展望
  • 檢測潛伏感染（皮膚檢測和IGRA）
  • 噬菌體試驗
  • 抗藥性檢測（DST）
  • 核酸檢測
  • 放射學方法
  • 細胞激素檢測試驗
  • 其他

第5章結核病診斷市場：依最終用途的估計和趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 全球結核病診斷市場：最終用途展望
  • 診斷實驗室
  • 醫院和診所
  • 其他

6. 結核病診斷市場：區域估計和趨勢分析（按產品、類型和最終用途）

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 2024年主要企業的市場佔有率/地位分析
  • 公司簡介
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
Product Code: GVR-1-68038-098-9

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.18 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • The latent infection detection segment (Skin Test & IGRA) led the market in 2024 with a 40.59% share, driven by the increasing prevalence of tuberculosis.
  • Drug Resistance (DST) is projected to achieve the fastest CAGR during the forecast period. DST evaluates the susceptibility of Mycobacterium tuberculosis to various antibiotics, identifying which drugs are effective for treatment.
  • In 2024, the diagnostic laboratories segment dominated the TB diagnostics market with the largest revenue share, driven by initiatives to enhance patient outcomes through accessible, retail-level diagnostic services.
  • The hospitals and clinics segment is poised for significant growth, driven by increasing TB testing rates in healthcare settings.
  • The tuberculosis diagnostics market in Asia Pacific dominated the market with revenue share of 37.18% in 2024 and is expected to witness the fastest growth over the forecast period.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Tuberculosis Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Tuberculosis Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Tuberculosis Diagnostics Market by Type Outlook
  • 4.4. Detection of Latent Infection (Skin Test & IGRA)
    • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.5. Phage Assay
    • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.6. Detection of Drug Resistance (DST)
    • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.7. Nucleic Acid Testing
    • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.8. Radiographic Method
    • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.9. Cytokine Detection Assay
    • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Tuberculosis Diagnostics Market by End Use Outlook
  • 5.4. Diagnostic Laboratories
    • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.5. Hospitals & Clinics
    • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Abbott
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology Type benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. QIAGEN
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology Type benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Thermo Fisher Scientific Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology Type benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. BD
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology Type benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. F. Hoffmann-La Roche AG
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology Type benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Hologic, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology Type benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Cepheid
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology Type benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. DiaSorin S.p.A.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology Type benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Hain Lifescience GmbH
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology Type benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Oxford Immunotec
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology Type benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 4 North America Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 8 Canada Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 12 Europe Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 13 UK Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 14 UK Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 16 Germany Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 17 France Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 18 France Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 20 Italy Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 22 Spain Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 Denmark Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 24 Denmark Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 25 Sweden Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 26 Sweden Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 28 Norway Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 32 Japan Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 33 China Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 34 China Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 India Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 36 India Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 38 Australia Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 46 Brazil Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 50 MEA Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 52 South Africa Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 56 UAE Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Tuberculosis Diagnostics market outlook
  • Fig. 9 Tuberculosis Diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Tuberculosis Diagnostics market driver impact
  • Fig. 15 Tuberculosis Diagnostics market restraint impact
  • Fig. 16 Tuberculosis Diagnostics market strategic initiatives analysis
  • Fig. 17 Tuberculosis Diagnostics market: Type analysis
  • Fig. 18 Tuberculosis Diagnostics market: Type outlook and key takeaways
  • Fig. 19 Detection of Latent Infection (Skin Test & IGRA) market estimates and forecast, 2018 - 2030
  • Fig. 20 Phage assay market estimates and forecast, 2018 - 2030
  • Fig. 21 Detection of Drug Resistance (DST) market estimates and forecast, 2018 - 2030
  • Fig. 22 Nucleic Acid Testing market estimates and forecast, 2018 - 2030
  • Fig. 23 Radiographic method market estimates and forecast, 2018 - 2030
  • Fig. 24 Cytokine detection assay market estimates and forecast, 2018 - 2030
  • Fig. 25 Others market estimates and forecast, 2018 - 2030
  • Fig. 26 Lumbar puncture market estimates and forecast, 2018 - 2030
  • Fig. 27 Nerve conduction studies market estimates and forecast, 2018 - 2030
  • Fig. 28 Electromyography market estimates and forecast, 2018 - 2030
  • Fig. 29 Others market estimates and forecast, 2018 - 2030
  • Fig. 30 Tuberculosis Diagnostics market: End use movement analysis
  • Fig. 31 Tuberculosis Diagnostics market: End use outlook and key takeaways
  • Fig. 32 Diagnostic laboratories market estimates and forecast, 2018 - 2030
  • Fig. 33 Hospitals & clinics market estimates and forecast, 2018 - 2030
  • Fig. 34 Others market estimates and forecast, 2018 - 2030
  • Fig. 35 Global Tuberculosis Diagnostics market: Regional movement analysis
  • Fig. 36 Global Tuberculosis Diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global Tuberculosis Diagnostics market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America: SWOT
  • Fig. 44 Europe SWOT
  • Fig. 45 Asia Pacific SWOT
  • Fig. 46 Latin America SWOT
  • Fig. 47 MEA SWOT
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 55 France market estimates and forecasts, 2018 - 2030
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 62 China market estimates and forecasts, 2018 - 2030
  • Fig. 63 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 64 India market estimates and forecasts, 2018 - 2030
  • Fig. 65 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 66 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 67 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 68 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 69 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Market share of key market players- Tuberculosis Diagnostics market
  • Fig. 77 Key Company Categorization
  • Fig. 78 Company Market Share/Position Analysis, 2024
  • Fig. 79 Strategic Framework